Further dissection of the bigger group of CDKN2Alow tumours in the test cohort and the TCGA cohort did not result in similar subgroup sizes, but yet resulted in different cut-offs with significant differences in prognosis, with patients with an intermediate expression of CDKN2A having a better prognosis as those with a low expression (Supplementary Figure 1). This evidence concerns the gene CDKN2A and neoplasm.